Minimal residual disease (MRD) monitoring by quantitative RT-PCR (RQ PCR) and FISH in chronic myelogenous leukemia (CML) patients treated with STI571 (Gleevec®).

被引：0
作者：
Roche, C
Grardel, N
Cornu-Soenen, V
Laï, JL
Roumier, C
Berthaud, P
Chatelain, N
Cosson, A
Facon, T
Preudhomme, C
机构：
[1] INSERM, CHU Lille, U524, Lab Hematol A, F-59045 Lille, France
[2] INSERM, CHU Lille, U524, Lab Cytogenet, F-59045 Lille, France
[3] INSERM, CHU Lille, Lab Hematol A, F-59045 Lille, France
[4] Novartis France, Div Oncol, Paris, France
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2578
引用
收藏
页码：615A / 615A
页数：1
相关论文
共 50 条
[21]   Analysis of chronic myeloid leukemia (CML) cases with minimal disease after interferon treatment by means of interphase FISH and quantitative RT-PCR [J].
Tchirkov, A ;
Giollant, M ;
Briancon, G ;
Travade, P ;
Tavernier, F ;
Tournilhac, O ;
Deméocq, F ;
Malet, P .
CYTOGENETICS AND CELL GENETICS, 1999, 85 (1-2) :87-87
[22]   Analytical performance characteristics of a quantitative RT-PCR assay of BCR-ABL for monitoring minimal residual disease in CML [J].
England, TE ;
Wong, P ;
Delaney, C ;
Fesseha, G .
CLINICAL CHEMISTRY, 2005, 51 :A183-A183
[23]   Quantification of residual disease in chronic myeloid leukemia patients treated by interferon using interphase FISH and competitive RT-PCR [J].
Tchirkov, A ;
Giollant, M ;
Briancon, G ;
Travade, P ;
Tournilhac, O ;
Demeocq, F ;
Kuleshov, N ;
Malet, P .
CYTOGENETICS AND CELL GENETICS, 1997, 77 (1-2) :P325-P325
[24]   Quantitation of minimal residual disease with real-time quantitative RT-PCR in patients treated with DLI for relapsed CML after BMT [J].
Schattenberg, A ;
Mensink, E ;
Schaap, N ;
de Witte, T .
BONE MARROW TRANSPLANTATION, 1999, 23 :S46-S46
[25]   Multiplex real-time quantitative RT-PCR for monitoring chronic myelogenous leukemia. [J].
Samoszuk, N ;
Tseng, RW .
BLOOD, 1999, 94 (10) :278B-278B
[26]   Minimal residual disease monitoring by quantitative real time-PCR during treatment with STI571 for bcr/abl-positive acute lymphoblastic leukemia. [J].
Martinelli, G ;
Piccaluga, PP ;
Malagola, M ;
Rondoni, M ;
Soverini, S ;
Amabile, M ;
Pane, F ;
Bianchini, M ;
Ottaviani, E ;
Giannini, B ;
Vigna, E ;
Bosi, C ;
Gaitani, S ;
Paolini, S ;
Russo, D ;
Visani, G ;
Fiacchini, M ;
Baccarani, M .
BLOOD, 2003, 102 (11) :245B-246B
[27]   Detection of minimal residual disease in chronic myeloid leukemia using a real time quantitative RT-PCR assay [J].
Bouraoui, S. ;
Dhouib, H. ;
Boughriba, R. ;
Weslati, M. ;
Ounissi, D. ;
Hazgui, M. ;
Dhraief, M. ;
Mezabi, S. Regaya .
VIRCHOWS ARCHIV, 2015, 467 :S199-S199
[28]   Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement [J].
S Viehmann ;
A Teigler-Schlegel ;
J Bruch ;
C Langebrake ;
D Reinhardt ;
J Harbott .
Leukemia, 2003, 17 :1130-1136
[29]   Prognostic relevance of minimal residual disease (MRD) analysis in BCR-ABL positive acute lymphoblastic leukemia (ALL) patients during Gleevec (STI571) therapy. [J].
Scheuring, UJ ;
Pfeifer, H ;
Brueck, P ;
Wassmann, B ;
Atta, J ;
Gschaidmeier, H ;
Petershofen, E ;
Hoelzer, DF ;
Ottmann, OG .
BLOOD, 2001, 98 (11) :762A-763A
[30]   Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement [J].
Viehmann, S ;
Teigler-Schlegel, A ;
Bruch, J ;
Langebrake, C ;
Reinhardt, D ;
Harbott, J .
LEUKEMIA, 2003, 17 (06) :1130-1136
12345